18 SkyePharma Annual Report 2004 Financial Review Turnover for DepoDur, Dr Reddys formerly Trigenesis Turnover for the year increased by 17% to 62.2 for the rights to certain dermatological assets million, compared with 53.2 million in 2003. and Quintiles for consenting to the transfer of the This is primarily due to higher royalty income US, Canadian and Mexican marketing rights for together with an increase in manufacturing and Solaraze to Bradley.
In addition, 7.2 million of distribution revenues, partly off-set by a fall in revenue was recognised from GlaxoSmithKline on contract development and licensing revenues.
the phase III clinical trials of Requip ropinirole, This increase does not include milestone payments AstraZeneca on the phase III clinical trials of of 5.5 million $10 million received during 2004 budesonide HFA and Novartis on the first European from Endo and First Horizon, which have not been approval of Foradil Certihaler and the phase II included in turnover and have been fully deferred clinical trials of QAB 149. to later years.
In April 2005 SkyePharma announced the licensing of DepoBupivacaine Royalty income increased by 39% to 26.0 million, for Europe to Mundipharma.
Royalty income in 2004 derives principally from Paxil CR, Contract development and licensing revenue Xatral OD, DepoCyt and Solaraze.
DepoDur decreased by 11% to 26.3 million due primarily was launched in December 2004 and is expected to the deferral of the above milestones received and to contribute to royalty income in 2005. the absence of anticipated milestones in the year from the expected approval of Triglide and the Manufacturing and distribution revenues more licensing of a package of products in the pulmonary than doubled to 9.9 million, compared with field.
As discussed in the review of operations 4.8 million in 2003, mainly due to increased the Triglide milestone has been triggered on FDA clinical and pre-launch production of the Foradil approval in May 2005, and the milestone on Certihaler for Novartis and Coruno for Therabel.
licensing of a package of products in the pulmonary field is still anticipated.
Revenues recognised from Deferred income milestone payments and payments received on the During 2004, the Group released a net 1.4 million signing of agreements amounted to 20.3 million from deferred income under its revenue compared with 24.2 million in 2003.
Amounts received included included revenue from Endo upon the FDA approval the milestones from Endo and First Horizon noted of DepoDur in the US, Zeneus formerly Medeus above which have been fully deferred.
The total for the European marketing and distribution rights deferral of 14.5 million at the end of 2004 comprises: Deferred income 31 December 31 December 2003 Received Recognised 2004 million million million million Contract development and licensing revenue 7.1 26.6 26.3 7.4 Other operating income 8.8 0.5 1.2 7.1 15.9 26.1 27.5 14.5 Includes exchange adjustments SkyePharma Annual Report 2004 19 Deferred contract development and licensing Other operating income At 31 December 2004 SkyePharma had cash income will be released in later years as the related Under the Paul Capital agreements, other and short term deposits of 15.3 million.
costs are incurred or as any associated obligations operating income recognised in 2004 was This compares with 22.0 million net of overdrafts under the relevant contracts are satisfied.
Other 1.2 million, compared with 6.1 million in 2003. at 31 December 2003 and 29.0 million net operating income deferred will no longer be All of the income under the first Paul Capital of overdrafts at 30 June 2004. recognised under International Financial Reporting agreement has now been recognised, and there is Standards IFRS.
7.1 million of deferred income under the second In 2004 there was a net cash outflow from Paul Capital agreement as at December 2004. operating activities of 10.7 million, compared Cost of sales Royalty payments to Paul Capital of 3.0 million with a net cash inflow of 6.6 million in 2003.
Cost of sales comprises research and 2003: 3.2 million were expensed during the year.
development expenditures, including the costs During the year the Group spent 7.9 million on of certain clinical trials incurred on behalf Operating results capital expenditure and fixed asset investments, of our collaborative partners: the direct costs The Groups operating loss before exceptionals fell including 4.4 million on tangible fixed assets.
of contract manufacturing: direct costs of by 59% to 9.7 million, compared with 23.4 million The Group also recorded fixed asset investments licensing arrangements and royalties payable.
in 2003 due principally to the reduction in other of 2.0 million and intangible assets of 1.0 million Cost of sales increased by 5% to 31.2 million administration expenses.
The increased turnover relating to the strategic alliance with Vectura in 2004, compared with 29.8 million in 2003. and lower selling, marketing and distribution in the area of pulmonary delivery technologies.
This was mainly due to increased manufacturing expenses together with lower research and The proceeds on disposal of the Groups and distribution costs on the higher production development expenses have also contributed to the non-strategic holding of Transition Therapeutics of the Foradil Certihaler for Novartis partly reduction of the operating loss before exceptionals.
offset by a fall in contract development and The operating loss after exceptionals also fell by licensing cost of sales.
The resulting gross profit 48% to 20.7 million.
The net loss fell by 44% to SkyePharma received 0.3 million of cash during increased by 33% to 31.0 million, compared 24.3 million in 2004, compared with 43.2 million the year from the issue of Ordinary Shares relating with 23.4 million in 2003. in 2003.
Earnings before interest, tax, depreciation to the exercise of employee share options over and amortisation EBITDA, a commonly used Ordinary Shares.
During 2004 the Group settled Expenses performance indicator, showed a 76% improvement the 0.5 million Chiron promissory note.
Selling, marketing and distribution expenses to a loss of 6.4 million in 2004 compared with decreased significantly by 60% to 1.7 million, a loss of 26.6 million in 2003.
Balance sheet reflecting the significant savings resulting from The Group balance sheet at 31 December 2004 the Group reorganisation announced last year.
The loss per share after exceptionals was 3.9 shows shareholders funds of 63.6 million 2003: Amortisation of intangible assets decreased pence, which compares with 7.1 pence in 2003.
Goodwill written off to the profit and slightly by 0.4 million to 6.3 million.
Other Foreign exchange movements negatively impacted loss account reserve remained at 147.6 million.
administration expenses before exceptionals turnover by 2.8 million in the year.
This was more were 12.2 million in 2004, compared with than offset by exchange benefits in costs, primarily At 31 December 2004 SkyePharma had fixed 18.0 million in 2003, a fall of 32%.
The decrease research and development costs.
The total impact asset investments totalling 20.1 million.
The was mainly due to one-off charges in 2003, on the net loss for the year was a benefit of investments include Astralis Ltd, a US company: including the cost of reacquiring the DepoCyt 1.6 million over 2003.
Micap plc, a UK company: Vectura Group plc, a European rights from Elan and from UK company and Vital Living Inc, a US company.
administration savings resulting from the Cash balances and cash flow The investment in Astralis has been treated as aforementioned reorganisation.
During 2004 the Group issued 20 million 6% an associated undertaking from December 2004, convertible bonds, with a first right of conversion when SkyePharma announced a transaction to The exceptional charge of 4.7 million mainly after five years by the holder of the bonds, and a acquire a significant equity position and additional relates to a write down in the value of fixed asset final maturity of May 2024.
In addition, the Group Board representation in Astralis so as to influence investments, and the continuing reorganisation exchanged 49.6 million of its convertible bonds its future strategic direction.
This has resulted of some research and development operations due 2005 for convertible bonds due 2024, leaving in goodwill of 13.7 million.
and other business functions which commenced 9.8 million of the 2005 bonds outstanding.
The reorganisation is expected Unamortised issue costs of 0.3 million were The Groups fixed asset investments are primarily to be completed during the first half of 2005. written off on exchange of the convertible bonds.
held in development stage pharmaceutical The 49.6 million 2024 convertible bonds were companies as long term investments associated SkyePharmas own research and development consolidated to form a single series with the with collaboration agreements or as part of expenses in the year decreased by 2.6 million 20 million 2024 bonds issued in 2004.
The bonds SkyePharmas long term strategy.
The Board to 28.0 million, mainly due to a reduction in are convertible at the option of the holder into continues to review the underlying performance expenditure on DepoDur when compared with the SkyePharma Ordinary Shares at a conversion price of the individual companies and the investments significant expenditure incurred in the prior year of 1.00.
This raised approximately 16.6 million have been recorded at the lower of cost or net in preparation for its July 2003 filing with the FDA.
Vital Living has been written 20 SkyePharma Annual Report 2004 Financial Review continued down by 3.5 million to the Directors assessment US GAAP new or expanded indications for its products, other of its net realisable value based on a number Under US GAAP, the Groups loss on ordinary regulatory risks, risks relating to SkyePharmas of considerations including the share price as activities would have been 20.8 million 2003: ability to manufacture pharmaceutical products at 31 December 2004.
The Group will continue to 38.6 million, and shareholders funds would on a large scale, risks that customer inventory monitor its investments and the underlying value be positive at 84.7 million 2003: 94.4 million.
will be greater than previously thought, risks of the companies closely.
The differences from UK GAAP relate principally concerning SkyePharmas ability to manage to the treatment of goodwill, revenue recognition, growth, SkyePharmas marketing partners ability Current asset investments comprise a 3.25 million sale of royalty interests and accounting for to market a pharmaceutical product on a large 5% convertible loan note from GeneMedix plc.
associates, as explained more fully in the scale and manage their sales and marketing This has been recorded at 1.1 million at Reconciliation to US accounting principles.
organisation and maintain or expand sales 31 December 2004, being the lower of cost and and market share for its products, risks relating net realisable value assuming conversion of the Subsequent events to the ability to ensure regulatory compliance, note into GeneMedix ordinary shares.
In April 2005 SkyePharma entered into an risks related to the research, development amendment agreement with GlaxoSmithKline and regulatory approval of new pharmaceutical At 31 December 2004 bank and other nonGSK in respect of Paxil CR.
Under the terms products, risks related to research and convertible debt amounted to 11.0 million 2003: of the amendment agreement, GSK will make development costs and capabilities, market 12.7 million consisting primarily of a 7.4 million a one-time payment of approximately $10 million.
acceptance of and continuing demand for 2003: 7.5 million property mortgage secured on In addition, SkyePharma will also be entitled SkyePharmas products and the impact of the Swiss assets.
In addition the company has 6% to an increase in the royalty rate from 3% to 4% increased competition, risks associated with convertible bonds due June 2005 of 9.8 million on actual net sales of Paxil CR, with effect from anticipated top and bottom line growth and 2003: 58.8 million and 6% convertible bonds March 2005.
As GSK has been unable to supply the possibility that upside potential will not due May 2024 of 66.5 million 2003: Nil.
Net debt Paxil CR in the US since March 2005, GSK has be achieved, competitive products and pricing, amounted to 72.0 million 2003: 49.5 million.
also agreed to pay SkyePharma the same level and risks associated with the ownership of royalty on GSKs budgeted sales of Paxil CR and use of intellectual property rights.
Throughout most of 2004 30 million of the 6% from March 2005 while the product remains SkyePharma undertakes no obligation to revise convertible bonds were subject to an interest rate off the market, subject to other terms of the or update any such forward looking statement swap agreement, swapping a fixed rate obligation agreement.
Approximately 5.0 million has to reflect events or circumstances after the date of 6% for a floating rate.
The weighted average been recorded as royalty income in 2004. of this Annual Report.
floating rate for the year was 6.82%, and the floating rate at 31 December 2004 was 7.14%.
On 31 May 2005 the Group announced that it had Donald Nicholson The swap is cancellable at the option of the bank.
signed agreements for a private placement of 20 Finance Director This will terminate in June 2005. million 8% convertible bonds, with a first put after five years by the holder of the bonds, and a final During 2004 SkyePharma issued 3.25 million maturity of May 2025.
The bonds are expected to be Ordinary Shares to the Research Development issued in June 2005.
The bonds are convertible at Foundation as a result of a restructuring of the the option of the holder into SkyePharma Ordinary historic arrangements with RDF existing at the Shares at a conversion price of 81 pence at any time of the DepoTech acquisition in 1999. time prior to maturity.
Unless previously redeemed or converted, the bonds will be redeemed by the International Financial Reporting Standards Group at their principal amount in May 2025.
The SkyePharma will be required to prepare consolidated two convertible bonds existing at 31 December financial statements under IFRS from 1 January 2005 2004, due in June 2005 and May 2024, are not and to restate the 2004 results for comparison.
The Group is completing a project to convert its Forward looking statements comparative financial information from UK GAAP The foregoing discussions contain certain to IFRS and plans to announce the results during forward looking statements that may involve a the first half of 2005.
The first SkyePharma number of risks and uncertainties.
Actual results financial statements prepared under IFRS will may vary significantly based upon a number of be for the period ending 30 June 2005.
The key factors, which are described in SkyePharmas differences that the Company expects to arise 20-F and other documents on file with the SEC.
on the adoption of IFRS are summarised in the These include without limitation risks in obtaining IFRS section of this report.
and maintaining regulatory approval for existing,
